Alaska Medicaid Pharmacy and Therapeutics Committee Meeting date May 20th, 2005 Frontier Building, 3601 C Street; Room 890/896

Agenda

Call in: 1-800-315-6338. Use access code 735#.



5 minutes

Noon or before

*Drug classes to be discussed as time allows.

Vote on motions

Closing

Final Comments by Chair or other members

Call to order - Chair Roll call Public Comment – Local Public / Local Physicians - (See guidelines on page 2)	Richard Brodsky, MD Richard Brodsky, MD	8:00 a.m. 8:00 – 8:05
Presentation Behavioral Pharmacy Management System (BPMS) Public Comment - (See guidelines on page 2)	Comprehensive Neuroscience, Inc. (CNS)	Approximately 8:15 a.m.
Re-review Antiherpes Virus Agents Time for discussion & vote Vote on motions	First Health Services Corp.	Time as needed
Public Comment - (See guidelines on page 2) Re-review Antifungals Time for discussion & vote Vote on motions	First Health Services Corp.	Time as needed
 Public Comment - (See guidelines on page 2) Re-review Oral Cephalosporins (Second Generation) Time for discussion & vote Vote on motions 	First Health Services Corp.	Time as needed
Public Comment - (See guidelines on page 2) Re-review Oral Cephalosporins (Third Generation) • Time for discussion & vote • Vote on motions	First Health Services Corp.	Time as needed
BREAK		Approx 10:30 a.m.
Public Comment - (See guidelines on page 2) Re-review Oral Macrolides • Time for discussion & vote	First Health Services Corp.	Approx 10:30 a.m. Time as needed
Public Comment - (See guidelines on page 2) Re-review Oral Macrolides • Time for discussion & vote	First Health Services Corp. First Health Services Corp.	
Public Comment - (See guidelines on page 2) Re-review Oral Macrolides • Time for discussion & vote • Vote on motions Public Comment - (See guidelines on page 2) Re-review Quinolones (Second Generation) • Time for discussion & vote		Time as needed

GUIDELINES FOR PROVIDING COMMENT to the ALASKA P&T COMMITTEE May 20th, 2005

- 1. All interested speakers will be required to provide the Committee with the name of their organization, the speaker's relationship to the organization and topic area.
- 2. The time on the agenda for each agenda item is limited. An individual's comments to the committee are limited to a maximum of five (5) minutes in total.
- 3. Only one speaker "slot" will be available per meeting representing a single manufacturer or interest group. Within the allowable five (5) minute time period, multiple speakers may share this "slot".
- 4. NO reference or information as to pricing is allowed in any comment(s). Such information will be considered reason for immediately ending the comment opportunity.
- 5. It is requested that comment provided in relation to specific medications be directed toward how this product is clinically superior or the specific advantage(s) it offers, new evidence/research results or synergistic outcomes which have been demonstrated.
- 6. Written medical information is not accepted at the P&T meeting. This is to be submitted First Health prior to the meeting.